Shares of biotech company Celsion (CLSN 3.84%) soared 10% in intraday trading after the company announced an agreement with Chinese drugmaker Zhejiang Hisun Pharmaceutical. With phase 3 clinical trial results for the company's flagship drug, ThermoDox, due to be released before the end of the month, this announcement has added a new dimension to this stock's story. In this video, our health care analysts Max Macaluso and Brenton Flynn break down the details of this agreement and discuss what investors must watch in the coming days.
Free Article
New Hope for Celsion Investors?
By Max Macaluso and Brenton Flynn
–
Jan 22, 2013 at 2:35PM
NASDAQ: CLSN
Celsion
Market Cap
$12M
Today's Change
(3.84%) $0.05
Current Price
$1.35
Price as of April 25, 2024, 10:12 a.m. ET
This agreement adds more suspense as investors await Phase 3 clinical trial results from Celsion.
Brenton Flynn has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.